Last reviewed · How we verify
NCT04533971
The Effect of a Series of Systemic Cryotherapy Treatments on the Functional State of Patients With Multiple Sclerosis
NA trial testing Whole body cryotherapy in Multiple Sclerosis (ICD10-G35) in 114 participants. Completed in 20 December 2019.
20 December 2019
Quick facts
| Lead sponsor | Pomeranian Medical University Szczecin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 114 |
| Start date | 1 April 2015 |
| Primary completion | 20 December 2019 |
| Estimated completion | 20 December 2019 |
Drugs / interventions tested
- Whole body cryotherapy — full drug profile →
Conditions studied
- Multiple Sclerosis (ICD10-G35) — all drugs for Multiple Sclerosis (ICD10-G35) →
Sponsor
Pomeranian Medical University Szczecin
Who can join
18 and older, any sex, with Multiple Sclerosis (ICD10-G35). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multiple sclerosis (Latin: Sclerosis multiplex; MS) is a chronic, inflammatory and degenerative disease of the central nervous system (CNS) characterised by a varied course and symptomatology. The chronic nature of the disease and gradual loss of tissue within the CNS result in increasing neurological deficits and motor failure over time. Due to the characteristics of the symptoms and the chronic course of MS, patients with MS use various forms of physiotherapeutic procedures throughout most of their lives, including especially often whole-body cryotherapy (WBC) treatments. The aim of this study was to assess potential changes in bioelectrical muscle activity during rest and contraction after exposure on 20 series of Whole body cryotherapy (WBC) in patients with multiple sclerosis (MS). Assessment potential relationships between the sEMG parameters and functional state in patients with multiple sclerosis pre and post 20 series of WBC. Finally, 114 patients with MS participated in the planned procedures of research. The participants were randomly assigned to the two groups, WBC and control. The sample size was 60 in WBC, and 54 in control groups. Testing before and after series of WBC consisted of: clinical assessment of fatigue was performed by the Fatigue Severity Scale (FSS), gait speed using Timed 25 Foot Walk (T25-FW), Hand grip strength (HGS), and surface electromyography (sEMG) of the dominant hand.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04533971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Pomeranian Medical University Szczecin trials
Trials by the same sponsor.
- NCT07370649 — Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study · not yet recruiting
- NCT07328789 — Factors Influencing Cardiac Rehabilitation Success · not yet recruiting
- NCT06809101 — Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Bal · recruiting
- NCT07070609 — Sagittal Spine Balance in Patients With Chest Wall Deformity · active not recruiting
- NCT06743360 — Microanalysis of Changes in 3D Geometry of Orthodontic Mini-implants · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04533971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pomeranian Medical University Szczecin
- Last refreshed: 24 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04533971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing